Neuropsychiatric side effects related to treatment with felbamate

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 8, Issue 3, 1996, Pages 341-346

  McConnell, Harry ^a   Snyder, Peter J ^b   Duffy, James D ^b   Weilburg, Jeffrey ^b   Valeriano, J ^b   Brillman, J ^b   Cress, Kim ^b   Cavalier, J ^b  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; FELBAMATE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; VALPROIC ACID;

ADULT; APATHY; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; HUMAN; IRRITABILITY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOSIS; SEIZURE;

EID: 0029791015     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.8.3.341     Document Type: Article

References (17)

1. Felbamate Study Group in Lennox-Gastaut Syndrome: Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med 1993; 328:29-33
2. Bourgeois B, Leppik IE, Sackellares JC, et al: Felbamate: a doubleblind controlled trial in patients undergoing presurgical evaluation of partial seizures. Neurology 1993; 43:693-696
3. Theodore WH, Raubertas RF, Porter RJ, et al: Felbamate: a clinical trial for complex partial seizures. Epilepsia 1991; 32:392-397
4. Fraught E, Sachdeo RC, Remler MP, et al: Felbamate monotherapy for partial onset seizures: an active-control trial. Neurology 1993; 43:688-692
5. McCage RT, Wasterlain CG, Kucharczyk N, et al: Evidence for anticonvulsant and neuroprotectant action of felbamate medicated by strychnine-insensite glycine receptors. J Pharmacol Exp Ther 1993; 264:1248-1252
6. Penix LP, Morin M, Wasterlain CG: Effect of felbamate on MK-801 binding (abstract). Epilepsia 1990; 31:642
7. Swinyard EA, Sofia RD, Kupferberg HJ: Comparative anticonvulsant activity and neurotoxicity of felbamate and four prototype antiepileptic drugs in mice and rats. Epilepsia 1986; 27:27-34
8. Rho JM, Donevain SD, Rogawski MA: Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and GABAA receptors. Ann Neurol 1994; 35:229-234
9. Rogawski MA, Porter RJ: Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 1990; 42:223-286
10. Rogawski MA: The NMDA receptor, NMDA antagonists and epilepsy therapy. Drugs 1992; 44:279-292
11. Albers GW, Goldberg MP, Choi DW: Do NMDA antagonists prevent neuronal injury? Yes. Arch Neurol 1992; 49:418-420
12. Introducing New Felbatol (felbamate). Wallace Laboratories, Division of Carter-Wallace, Inc., July 13, 1993
13. Spitz MC, Towbin J, Shantz D: Felbamate: initial experience in adults with epilepsy (abstract). Epilepsia 1994; 35:95
14. Kanner AM, Ruzica R, Smith M: Acute depressive disorder following a three week switch-over to felbamate: a controlled study (abstract). Epilepsia 1994; 35:95
15. King JA: Increased incidence of adverse behavioral side effects associated with the addition of felbamate (FBM) to antiepileptic drug (AED) regimens in the mentally retarded (MR) population (abstract). Epilepsia 1994; 35:95
16. Sasso E, Delsoldato S, Negrotti A, et al: Reversible valproate-induced extrapyramidal disorders. Epilepsia 1994; 35:391-393
17. Ketter TA, Marlow BA, Flamini R, et al: Anticonvulsant withdrawalemergent psychopathology. Neurology 1994; 44:55-61